Shareholding disclosure

Aviva Plc

Declared position

7.84%

Threshold

Crossed upwards

Timeline

Published

11.02.2017

Transaction

06.02.2017

Voting rights breakdown

Voting rights acquired7.84%

Voting rights sold0%

Below threshold0%

Notice details

CategorySingle shareholder

ExchangeXSWX

Notification ID

TAH2900027

Beneficial owner

Aviva Plc

Declared address

Aviva Plc, LONDON EC3P 3DQ

transfer-in of new funds resulting in a new direct shareholder

Open shareholder profile Open company profile

Back to the feed

Shareholding disclosure

Aviva Plc

Newron Pharmaceuticals S.p.A.11.02.2017TAH2900027

Disclosure summary

Aviva Plc disclosed a holding in Newron Pharmaceuticals S.p.A. on the acquisition side, published by SIX Exchange Regulation on 11.02.2017, at 7.84% of voting rights. Notice category: Single shareholder.

Disclosed position

7.84%

Voting rights acquired

Voting rights acquired7.84%

Voting rights sold0%

Below threshold0%

Never miss a market signal again

Create a free account

Need more? Discover the Pro plan

Pro alertsEmail and Telegram after publication

Unlimited company trackingUnlimited watchlist with the Pro plan

Monday recapYour stocks' essentials at the open

Disclosure detail

Aviva Plc disclosed a holding in Newron Pharmaceuticals S.p.A., published on 11.02.2017.

Publication date11.02.2017

Transaction date06.02.2017

Issuing companyNewron Pharmaceuticals S.p.A.

Beneficial ownerAviva Plc

Declared addressAviva Plc, LONDON EC3P 3DQ

CategorySingle shareholder

Voting rights acquired7.84%

Voting rights sold0%

Below threshold0%

ExchangeXSWX

Notification IDTAH2900027

Conditions

transfer-in of new funds resulting in a new direct shareholder

Source: SIX Exchange Regulation · Publication date: 11.02.2017

These figures aggregate public disclosures. They are not investment advice.

insider24.ch

Never miss a market signal again

Create a free account

Need more? Discover the Pro plan

Pro alertsEmail and Telegram after publication

Unlimited company trackingUnlimited watchlist with the Pro plan

Monday recapYour stocks' essentials at the open